Page last updated: 2024-11-03

probenecid and Obesity, Morbid

probenecid has been researched along with Obesity, Morbid in 1 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Obesity, Morbid: The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adenwalla, HN1
O'Connor, CR1

Other Studies

1 other study available for probenecid and Obesity, Morbid

ArticleYear
Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2011, Volume: 17, Issue:7

    Topics: Adult; Catastrophic Illness; Drug Therapy, Combination; Febuxostat; Glycogen Storage Disease Type I;

2011